Amplia Therapeutics Limited (ATX.XA)
| Previous close | 0.0610 |
| Open | 0.0580 |
| Bid | 0.0560 x N/A |
| Ask | 0.0640 x N/A |
| Day's range | 0.0560 - 0.0630 |
| 52-week range | 0.0560 - 0.1150 |
| Volume | |
| Avg. volume | 26,269 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US
Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce that the US FDA have cleared Amplia's IND application for a trial of Amplia's best-in-class focal adhesion kinase (FAK) inhibitor narmafotinib in pancreatic cancer. The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.
- PR Newswire
AACR OVARIAN CANCER CONFERENCE PRESENTATION
Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company") is pleased to announce that a poster, detailing a series of preclinical studies in ovarian cancer models, was presented at the American Association for Cancer Research (AACR) Special Conference In Cancer Research: Ovarian Cancer meeting, held in Boston, USA over the weekend. The poster describes research with narmafotinib (AMP945) conducted by the company's collaborators at the University of California, San Diego (UCSD), and was
- PR Newswire
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in combination with FOLFIRINOX treatment. FOLFIRINOX, a combination of four chemotherapies used in the treatment of pancreatic cancer patients, is currently a widely-used treatment in many major markets around the world including the US.
